LivaNova Appoints Anne Liddy as Chief Legal Officer
Liddy brings more than two decades of experience advising global healthcare and life sciences companies on complex legal, regulatory, M&A, and compliance matters. She joins
“Anne is a highly accomplished executive with an established record of achievement, guiding organizations through complex regulatory and business environments,” said Vladimir Makatsaria, Chief Executive Officer of
Prior to her role as General Counsel, Liddy held leadership positions of increasing responsibility within Hologic’s legal organization, with oversight spanning commercial, intellectual property, employment, compliance, and litigation matters. Earlier in her career, she served as Corporate Counsel at Pfizer, Inc., supporting the consumer healthcare business. She began her legal career at
“I am honored to join
Liddy holds a Bachelor of Arts degree from the
About LivaNova
LivaNova PLC is a global medical technology company built on nearly five decades of experience and a vision to change the trajectory of lives for a new day. Through ingenious medical solutions in select neurological and cardiac conditions, LivaNova strives to ignite patient turnarounds. Headquartered in London, with approximately 3,300 employees and a presence in more than 100 countries, LivaNova serves patients, healthcare professionals, and healthcare systems worldwide. For more information, please visit www.livanova.com.
Safe Harbor Statement
This news release contains “forward-looking statements” concerning the Company’s goals, beliefs, expectations, strategies, objectives, plans, underlying assumptions, and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding changes to the Company’s executive leadership. Actual events may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company’s most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. LivaNova undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260605879489/en/
LivaNova Investor Relations and Media Contacts
+1 281-895-2382
Briana Gotlin
VP, Investor Relations
InvestorRelations@livanova.com
Deanna Wilke
VP, Corporate Communications
Corporate.Communications@livanova.com
Source: LivaNova PLC